Review on recent advances of anti-HVC drugs

Chinese Pharmaceutical Journal

Volumn 39, Issue 6, 2004, Pages 403-408

  Zou, Jian ^a   Chen, Hong Shan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA DEXTRO 2' METHYLRIBOFURANOSYLGUANOSINE; CILUPREVIR; GUANOSINE DERIVATIVE; HISTAMINE; HYPERICIN; INTERFERON; ISIS 14803; JTK 003; LEVOVIRIN; MERIMEPODIB; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAMIDINE; RIBAVIRIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VP 50406; XTL 002;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; CHIRALITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; REPLICON; REVIEW;

EID: 4644297563     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends [J]. Semin Liver Dis, 2000, 20 (1): 16.
2. Shimotohno K. Hepatitis C virus and its pathogenesis [J]. Semin Cancer Biol, 2000, 10: 233.
3. Ohba K, Mizokami M, Lau JYN, et al. Evolutionary relationship of hepatitis C, pesti-flavi-planviruses, and newly discovered GB hepatits agents [J]. FEBS Letters, 1996, 378: 232.
4. Bartenschlager R, Lohmann V. Replication of hepatitis C virus [J]. J Gen Virol, 2000, 81: 1631.
5. Lesburg CA, Radfar R, Weber PC. Recent advances in the analysis of HCV NS5b RNA dependent RNA polymerase [J]. Curr Opin Investig Drugs, 2000, 1: 289.
6. Zein NN. Clinical significance of hepatitis C virus genotypes [J]. Clin Microbiol Rev, 2000, 13: 223.
7. Fried M, Shiffman ML, Reddy KR, et al. Pegylated (40 Kda) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively controlled, multicenter study [abstract] [J]. Gastroenterology, 2001, 120(Suppl): A-55.
8. Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon-α2b and ribavirin in combination: an Italian pilot study [J]. Eur J Gastroenterol Hepatol, 2002, 14: 477.
9. Chang CC, Chen TT, Cox BW, et al. Evolution of a cytokine using DNA family shuffling [J]. Nature Biotechnol, 1999, 17: 793.
10. Pockros PJ. Developments in treatment of chronic hepatitis C [J]. Expert Opin Invest Drugs, 2002, 11:1.
11. Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection [J]. Hepatology, 2002, 35: 1002.
12. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin [J]. Curr Opin Investig Drugs, 2002, 3(5): 680.
13. McHutchison JG, Cheung R, Shiffman ML, et al. A 4-week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C [Abstract] [J]. Hepatology, 2001, 34(Suppl): 329A.
14. Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C [J]. Hepatology, 2000, 32: 630.
15. Craxi A, Lo Iacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck [J]. J Hepatol, 2001, 35: 527.
16. Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity [J]. J Biomol Screening, 2002, 7: 149.
17. Ingallinella P, Fattori D, Altamura S, et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus [J]. Biochemistry, 2002, 41: 5483.
18. Fischmann TO, Weber PC. Peptidic inhibitors of the hepatitisC virus serine protease within non-structural protein 3 [J]. Curr Pharm Des, 2002, 8: 2533.
19. Narjes H, Yong CL, Steinmann G. Tolerability and pharmaco kinetics of BILN 2061, a novel HCV serine protease inhibitor, after oral single doses of 5 to 2400 mg in healthy male subjects [J]. Hepatology, 2002, 36 (Suppl. 4, Pt.2): 800
20. Ingallinella P, Fattori D, Altamura S, et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus [J]. Biochemistry, 2002, 41: 5483.
21. Beaulieu PL, Llinas-Brunet M. Therapies for hepatitis C infection: targeting the non-structural proteins of HCV [J]. Curr Med Chem, 2002, 1: 163.
22. Sommadossi JP, Lacolla P. Methods and compositions for treating hepatitis C virus [P]. Int Patent Appl, WO 01/190121, 2001, Idenix Pharmaceuticals.
23. McHutchison JG, Patel K. Future therapy of hepatitis C [J]. Hepatology, 2002, 36 (Suppl 1): 245.
24. Myles DC. Recent advances in the discovery of small molecule therapies for HCV [J]. Curr Opin Drug Discov Devel, 2001, 4: 411.
25. Witherell G. ISIS-14803 (Isis Pharmaceuticals) [J]. Curr Opin Invest Drugs, 2001, 2: 1523.
26. Takeshi I, Satoshi O. Down-regulation of a gene expression by a novel antisense BNA oligonucleotide [J]. Nippon Yakurigaku Zasshi (Japanese), 2002, 120: 85.
27. Macejak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus (HCV)- RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes [J]. Hepatology, 2000, 31: 769.
28. Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV [J]. J Infect Dis, 2002, 185: 153.
29. Jeffrey MJ, Lawrence F. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection [J]. Antimicrob Agents Hemother, 2001: 517.
30. Bartenschlager R. Innovation: hepatitis C virus replicons: potential-role for drug development [J]. Nat Rev Drug Discov, 2002, 1: 911.
31. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers [J]. Nat Med, 2001, 7: 927.
32. Ilan E, Eren R, Lubin I, et al. The Trimera mouse: a system for generating human monoclonal antibodies and modeling human diseases [J]. Curr Opin Mol Ther, 2002, 4: 102.